Trials / Completed
CompletedNCT00143273
Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation
Dose Response Study Of Lasofoxifene In Postmenopausal Women With Osteoporosis (Placebo-Controlled, Multicenter, Double-Blind, Comparative Study) - Japanese Asian Dose Evaluation: JADE
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 497 (actual)
- Sponsor
- Ligand Pharmaceuticals · Industry
- Sex
- Female
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To establish the optimal dose of lasofoxifene that is fully effective in increasing the BMD in postmenopausal Asian women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lasofoxifene | 0.05 mg tablets |
| DRUG | Placebo | 0 mg |
| DRUG | Lasofoxifene | 0.25 mg tablets |
| DRUG | Lasofoxifene | 0.5 mg tablets |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2006-03-01
- Completion
- 2006-03-01
- First posted
- 2005-09-02
- Last updated
- 2011-08-10
Locations
17 sites across 3 countries: Japan, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT00143273. Inclusion in this directory is not an endorsement.